In a conscious dog model, coadministration of compound 4 and glucose afforded a significant improvement in portal vein GLP-1 secretion and glucose reduction, showing its potential to be a useful therapeutic for metabolic disorders. This evidence concerns the gene GCG and metabolic disease.